摘要:
A pharmaceutical composition comprising an anticholinergic and a steroid, optionally together with a pharmaceutically acceptable excipient, the anticholinergic and the steroid optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.
摘要:
Fluorenecarboxylic acid esters of general formula 1 1 wherein Xnull and the groups A, R, R1, R2, R3, R3null, R4, and R4null have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
摘要:
A pharmaceutical preparation comprising: (a) an active substance comprising a tiotropium salt, in a concentration based on tiotropium of between 0.0005 and 5% by weight; (b) a solvent selected from water or a water/ethanol mixture; (c) acid for achieving a pH between 2.0 and 4.5; and (d) a pharmacologically acceptable preservative, optionally including a pharmacologically acceptable complexing agent, stabilizer, a pharmacologically acceptable cosolvent, or other pharmacologically acceptable adjuvants and additives; a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler, and a method of treating asthma or COPD in a patient using the pharmaceutical preparation.
摘要:
The present invention relates to capsules for holding pharmaceutical preparations for powder inhalers with increased drug safety and capsules for pharmaceutical preparations for powder inhalers with improved adaptation to their use in powder inhalers. The capsules consist of water-insoluble hydrophobic synthetic materials which do not significantly affect the pharmaceutical quality of the contents themselves, but which improve the usability of the filled capsules with regard to their function, their longevity and/or the geographic location of their use, and are advantageous at various stages from manufacture up to utilisation.
摘要:
The invention relates to the use of (1null.2null,4null.5null.7null)-7-null(hydroxydi-2-thienylacetyl)oxynull-9,9-dimethyl-3-oxa-9-azoniatricyclonull3.3.1.02,4null nonane salts for preparing a pharmaceutical composition for the prevention and treatment of diseases associated with inflammation.
摘要:
The present invention relates to novel pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors, processes for preparing them and their use in the treatment of respiratory tract diseases.
摘要:
The present invention relates to atomizers for administering liquids to the cornea or conjunctiva of the eye, special eye adapters for atomizers and the use of atomizers for ophthalmological administration. The atomizers according to the invention are free from propellant gas and have an energy reservoir for supplying the energy needed for the atomization process.
摘要:
A liquid, propellant-free pharmaceutical preparation comprising: (a) a first active substance comprising a tiotropium salt, in a concentration based on tiotropium of between 0.0005% and 5% by weight; (b) a second active substance selected from the group consisting of: an antiallergic, antihistamine, steroid, and leukotriene antagonist; (c) a solvent selected from water or a water/ethanol mixture; and (d) a pharmacologically acceptable preservative, wherein the pH of the preparation is adjusted to between 2.0 and 4.5 with an acid and the tiotropium salt is dissolved in the solvent, optionally including a pharmacologically acceptable complexing agent, stabilizer, a pharmacologically acceptable cosolvent, or other pharmacologically acceptable adjuvants and additives; a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler, and a method of treating asthma or COPD in a patient using the pharmaceutical preparation.
摘要:
A method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound 1-nullN2-null3,5-dibromo-N-nullnull4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinylnull-carbonylnull-D-tyrosylnull-L-lysylnull-4-(4-pyridinyl)-piperazinenullBIBN4096BSnull or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof, as well as to the corresponding pharmaceutical compositions and the preparation thereof.